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Quercetin and biapigenin are antioxidant and neuroprotective compounds present in Hypericum perforatum, with potential application in 
neurodegenerative diseases. Quercetin has shown to have excellent antioxidant activities. Biapigenin possesses a distinctive mechanism of 
action, preventing the onset of calcium deregulation and mitochondrial dysfunction. The main aim of this study was to establish a new 
delivery system encapsulating H. perforatum neuroprotective fraction, isolated from it,containing quercetin and biapigenin into poly(-
caprolactone) (PCL) nanoparticles. It also aimed to study its hepato-protective potential. Different formulation parameters were optimized, 
resulting in a stable formulation of polymer:compounds ratio 1:0.1 with a mean particle size of 185 nm, zeta potential around −20 mV and 
association efficiency close to 100%. Compounds in vitro release, under physiological conditions, showed an initial burst followed by a 
sustained release. The antioxidant functional properties of these compounds were not altered by encapsulation. PCL-loaded nanoparticles 
protected HepG2 cells from intrinsic compound toxicity at high concentrations. Depending on the incubation regimen, quercetin-biapigenin ti-oxi
PCL-loaded nanoparticles or free compounds were more effective in protecting HepG2 cells against tert-butylhydroperoxide-induced 
toxicity. This is the first report of the encapsulation of a quercetin-biapigenin mixture in a polymeric matrix, specifically, in PCL, with 
synergic anti-oxidant and hepatoprotective effects.Keywords: Hypericum perforatum; Quercetin; Biapigenin; Nanoparticles; An. Introduction
The central nervous system (CNS) is known being particu-
arly sensitive to oxidative stress, which can be described as an
mbalance between generation and elimination of reactive oxygen
pecies (ROS) and reactive nitrogen species (RNS).dant Hepatoprotective; In vitro release
By-products of cells’ energy production, ROS and RNS, result
from the cellular redox process. These species play a dual effect
either as toxic and/or beneficial compounds. At low or moderate
levels, ROS and RNS exert beneficial effects on cellular responses
and immune function [1]. At high concentrations, a disturbance
in the pro-oxidant/antioxidant balance in favor of the pro-oxidant
state may occur, which can lead to cell damage. Oxidative damage
is, therefore, associated with aging and the development of several
diseases such as cardiovascular and neurodegenerative disorders,
cancer and diabetes, resulting in the loss of membrane integrity,
structural and functional changes in proteins and gene mutations.
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mOS and RNS generated during the body’s metabolic reactions can
eact with some cellular molecules, such as lipids, proteins and
NA, damaging them [1,2].
It is therefore important to preserve redox environment and
itochondrial function of the cell. This can be achieved by avoid-
ng the causes of oxidative stress and strengthen the defenses with
he usage of endogenous antioxidants and the intake exogenous
ntioxidants [3]. Besides their usage in the prevention of neu-
odegenerative diseases, antioxidants could also be relevant on its
reatment, as a single compound or in supplementary combination
ith drugs targeting other pathogenic mechanisms [4].
H. perforatum has been used as a medicinal plant for centuries,
or the treatment of external and internal disorders, such as minor
urns, wounds, skin inflammation, nerve pain, anxiety and mild
o moderately severe depression, competing for status as a stan-
ard antidepressant therapy and being a valid herbal alternative to
ynthetic antidepressants [5].
H. perforatum extracts and compounds also showed to have
elevant antioxidant and neuroprotective properties [2,6–9].
pecifically, a purified fraction containing quercetin and biapi-
enin has been extensively studied regarding its antioxidant and
europrotective properties [6–9]. Quercetin has been described to
rotect against several oxidative insults and several types of ROS
8],and is considered the most potent scavenger of ROS, RNS and
eroxynitrite of the flavonoid family [10]. Its ability to interactwith
ultiple cellular targets is likely the basis of its pharmacologi-
al activity [11]. In vivo quercetin activity remains controversial.
uercetin presents low aqueous solubility and instability in phys-
ological medium [12], depending on temperature and pH, which
imits its bioavailability, reduces permeability, and suffers exten-
ive first pass metabolism before reaching the local of action [13].
iapigenin is a less studied compound, possessing a distinctive
echanism of action, compared to quercetin. It was shown to
revent the onset of calcium deregulation and mitochondrial dys-
unction, affectingmitochondrial bioenergetics [6,8,9]. Antioxidant
ctivities of biapigenin have also been reported through its lipid
eroxidation inhibition potential [6,7].
One alternative to circumvent bioavailability problems is to
ntrap or adsorb the compounds into nanoparticles. The advan-
agesofusingnanoparticles fordrugdelivery result fromtheir small
ize, which allows them to penetrate within small capillaries and
e taken up within the cells, with efficient drug accumulation at
he target sites in the body. It also allows sustained drug release
ithin the target site over a period of days or even weeks after
dministration. [14]. Nanosystems employed for CNS targeted drug
elivery includepolymeric nanoparticles that comparedwith other
olloidal carriers, are a relevant alternative. PCL is a semi-crystalline
ydrophobic polymer, degraded by hydrolysis of its ester linkages
nderphysiological conditions. Its highpermeability tomanydrugs
nd a lack of toxicity has made PCL and its derivates well suited for
rug delivery [15].
Liver is essential for survival because of its role in the coordi-
ation of the body’s metabolism, including glucose homeostasis,
enobiotic metabolism and detoxification. All organs are vulner-
ble to oxidative stress. However, because of the high metabolic
ctivity of hepatocytes, liver is highly susceptible to oxidative stress
nd amajor target of toxic substances. Biotransformation of certain
enobiotics can also produce short-lived, unstable, highly reac-
ive chemical species, such as ROS and RNS that can interact with
unctional biomolecules and lead to adverse effects, resulting in
nflammatory and fibrotic liver disorders [16].Human hepatocellular carcinoma cells (HepG2) is a widely used
uman in vitro model for hepatic toxicity studies, including antiox-
dants that can be assayed with minor variations [16]. HepG2 cells
etain many of the specialized functions characteristic of nor-
al human hepatocytes, including the synthesis and secretion ofplasma proteins, phase I, phase II and antioxidant enzymes, being
good tool to studyhepatic toxicology, cytoprotective, andantigeno-
toxic effects of compounds [17].
The main aim of this study was to establish a nanoparticulate
system for the use of a neuroprotective fraction of H. perforatum
containing quercetin and biapigenin, using the synthetic polymer
PCL, by solvent displacement technique. The physical and morpho-
logical parameters of the nanoparticles were investigated, as well
as its in vitro release profile. Furthermore, the antioxidant activi-
ties of the compounds and of its nanoparticles were determined.
The potential protective effect of quercetin-biapigenin and its PCL-
loaded nanoparticles against t-BOOH-induced oxidative stress in
HepG2 cells was also studied.
2. Material and methods
2.1. Materials
Dulbecco’s Modified Eagle Medium (DMEM), antibiotic-
antimycotic solution, glutamine, trypsin-ethylenedi aminete-
traacetic acid (EDTA) solution, 3-(4,5-dimethy lthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT), PCL, Pluronic
®
F-68, DPPH,
nitroblue tetrazolium (NBT), reduced formof nicotinamide adenine
dinucleotide (NADH), N-phenylmethazonium methosulfate (PMS),
quercetin, biapigenin, curcumin, ferrozine, trichloroacetic acid and
tiobarbituric acid were purchased from Sigma-Aldrich Chemicals
Co. (St. Louis, MO, USA). Diethyl ether and acetone were pur-
chased fromMerck (Germany). SephadexLH-20andpolyamideCC6
acquiredwere fromGEHealthcare Life Sciences (UK). L(+)-Ascorbic
acid and pyruvate were purchased from Panreac(Barcelona, Spain).
EDTA was purchased from VWR (Portugal). Fetal Bovine Serum
(FBS)waspurchased fromBiochromKG(Berlin,Germany). All other
reagents used were for analytical grade.
2.2. Methods
2.2.1. Isolation of a neuroprotective Hypericum perforatum
fraction containing quercetin and biapigenin
H. perforatumplants (aerial portion)were collected in the region
of Braga, North of Portugal, and the biomass was freeze-dried on
the sameday, in a Labconco lyophilizer at 0.01mBar for 4days,with
a condenser surface temperature of −90 ◦C.
Amethanolic extractwaspreparedbymaceratingplant biomass
(100g dwb/L) with a methanol-water solution (80:20, V/V), for
4days, at room temperature and in darkness. The mixture was fil-
tered through a paper filter (Whatman, No. 1) and the resulting
methanolic extract was used for further processing. The acidi-
fied extract (pH 3) was fractionated by liquid–liquid extraction
with diethyl ether and the resulting fraction concentrated, under
reduced pressure, at 35 ◦C, in darkness. This ether fraction was fur-
ther subjected to Sephadex LH-20 column chromatography, eluted
with methanol. A selected fraction containing quercetin and biapi-
geninwas collected, concentrated, and purified through Polyamide
CC6 column. Compounds identification was performed by HPLC-
DAD as previously described [18]. Chromatograms were recorded
at 260, 350 and 590nm, and quercetin and biapigenin were quan-
tified (350nm) by the external method, using pure commercial
standards. This fraction is composed solely by quercetin and biapi-
genin and will be referred wherein as quercetin-biapigenin.
2.2.2. Production of quercetin-biapigenin poly-(-caprolactone)
(PCL) nanoparticles
Different formulations of quercetin-biapigenin loaded PCL
nanoparticles (PCL: quercetin-biapigenin ratio of 1:0.1; 1:0.2 and
1:0.5) were prepared by nanoprecipitation, as described elsewhere
[19]. Briefly, the corresponding mass of quercetin-biapigenin and
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P.5mg of polymer were dissolved in 1mL of acetone, trans-
erred, drop by drop, into 10mL of a Pluronic
®
F-68 aqueous
olution and stirred at 550 rpm for 3h. After that, nanoparticle
uspension was centrifuged at 15000 rpm for 30min at 4 ◦C and
upernatant discharged. Nanoparticles were washed with MilliQ-
ater, lyophilized and stored in a moisture free environment for
urther use. Freeze-drying conditions were of 0.01 mBar, for 3days,
ith a condenser surface temperature of −90 ◦C.
.2.3. Mean particle size and zeta potential analysis
The mean particle size and polydispersity index (PI) of the
anoparticles were determined by Dynamic Light Scaterring (DLS)
sing a Zetasizer NanoZS (Malvern Instruments, Ltd, UK). Zeta
otential determination was performed by laser doppler micro-
lectrophoresis, with the same equipment. The samples were
iluted 10-times with MilliQ-water for analysis. Each sample was
easured by three independent measurements, with three replica
ach, and the results are shown as mean± standard deviation.
.2.4. Association efficiency, loading capacity and production
ield
For the association efficiency (AE) determination, nanoparticles
uspension was centrifuged, the supernatant was collected and
nalyzed by HPLC-DAD, as previously described [18]. The amount
f quercetin and biapigenin encapsulated was determined by the
ollowing formula:
AE(%) = [(Total amount of compounds−Free compounds
in supernatant)/Total amount of compounds]×100
Loadingcapacity (LC)wasdeterminedby thedifferencebetween
he initial amount of compounds used to prepare the nanoparticles
nd the amount present in the supernatant after centrifugation.
otal weight of nanoparticles was determined by lyophilization of
n aliquot of hydrated nanoparticles.
LC(%) = [(Total amount of compounds−Free compounds
in supernatant)/Totalweight of nanoparticles]×100
Nanoparticles yield was determined taking in consideration the
nal weight of the nanoparticles (after lyophilization) and the ini-
ial amount of compounds to be encapsulated and polymer used in
ts preparation.
Yield(%) = (Totalweight of nanoparticles/Totalweight of
compounds andpolymer fed initially)×100
Each samplewas analyzed as three independent sets, with three
eplica each. The results are shown as mean± standard deviation.
.2.5. Nanoparticle morphology by transmission electronic
icroscopy
Morphologic analysis of the nanoparticles was performed by
ransmissionelectronicmicroscopy (TEM), usingaTEMZeissmodel
02C,80KV.TEMsampleswere stainedwithuranyl acetate1%solu-
ion, and placed on copper grids. The excess of water was removed
sing a filter paper, and gridswere left at room temperature for one
inute to dry prior to imaging..2.6. Fourier transform infrared spectroscopy (FTIR)
pectroscopy
Quercetin-biapigenin loaded PCL nanoparticles and unloaded
CL nanoparticles, were analyzed by FTIR spectroscopy to assessdrug-polymer interactions upon encapsulation. Control samples of
quercetin-biapigenin and its physical mixture with PCL polymer,
were also collected. All FTIR spectra were collected from 100 scans,
in the 4000–600 cm−1 range at 4 cm−1 resolution, on aABBMB3000
FTIR (ABB, USA). After data collection, all spectra were normalized
for further comparison.
2.2.7. In vitro release profile
Quercetin-biapigenin loaded PCL nanoparticles were dispersed
in phosphate buffered saline (PBS) (pH 7.4) containing ethanol 10%
(V/V) and incubated at 37 ◦C under magnetic stirring at 100 rpm.
Samples were taken at predetermined time intervals of 0.5, 1, 2,
4, 8 and 24h. The collected samples were centrifuged and the
quercetin and biapigenin content in the supernatant was deter-
mined by HPLC. All samples were run in three independent sets,
each composed by three replica, and the results are shown as
mean± standard deviation.
2.2.8. In vitro antioxidant activity
2.2.8.1. 2,2-diphenyl-1-picrylhydrazyl (DPPH)-radical scavenging
activity assay. The free radical-scavenger activity was deter-
mined by the DPPH assay, as described previously [7]. Briefly,
after adding different concentrations of the free compounds and
quercetin-biapigenin loaded PCL nanoparticles to DPPH (90M),
the percentage of remaining DPPH was determined continuously
from the absorbance at 515nm using a plate reader spectropho-
tometer, until a plateau state. At this time the percentage of
remaining DPPH was plotted against the concentration of the
compounds/loaded-PCL nanoparticles and the amount of antioxi-
dant necessary to decrease by 50% the initial DPPH concentration
(EC50) was calculated, using Graph Pad Prism 5.0
®
software.
Quercetin was used as positive control. All measurements were
performed in three independent sets, each composed by three
replica, and results are shown as mean± standard deviation.
2.2.8.2. Evaluation of superoxide radical scavenging activity. The
superoxide radical scavenging activity was determined using the
PMS-NADH nonenzymatic assay as previously described [20]. The
reaction mixture in the sample wells consisted of NADH (166M),
NBT (43M), free compounds andquercetin-biapigenin loadedPCL
nanoparticles and PMS (2.7M), in a final volume of 300L. All
components were dissolved in phosphate buffer (19mM, pH 7.4).
The assays were performed at room temperature during 2min and
startedwith the addition of PMS. Ascorbic acidwas used as positive
control. The sample concentration providing 50% inhibition (EC50)
was obtained by plotting the inhibition percentage against extract
concentrations, using Graph Pad Prism 5.0
®
software. All measure-
ments were performed in three independent sets, each composed
by three replica and results are shown as mean± standard devia-
tion.
2.2.8.3. Iron (II) chelating activity. The iron chelating activity of the
free compounds and quercetin-biapigenin loaded PCL nanopar-
ticles was evaluated as described previously [21] with some
modifications. Briefly, 50L of free compounds and PCL-loaded
nanoparticles at different concentrations were added to a solution
of 0.12mM of FeSO4 (50L) and 50L of Ferrozine (0.6mM). Then
the mixture was shaken vigorously and left standing at room tem-
perature for 10min. Absorbance of the solutionwas thenmeasured
spectrophotometrically at562nm.EDTAwasusedasapositive con-
trol. The ability of the free compounds and quercetin-biapigenin
loaded PCL nanoparticles to chelate ferrous ion was calculated rel-
ative to the control using the formula:
Chelatingactivity(%) = (Abscontrol−Abssample)/Abscontrol×100
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pThe sample concentration that chelates 50% of the ferrous
on (EC50) was calculated, using Graph Pad Prism 5.0
®
soft-
are. All measurements were performed in three independent
ets, each composed by three replica and results are shown as
ean± standard deviation.
.3. Cell culture
HepG2 cell line was obtained from the American Type Cul-
ure Collection (ATCC) and cultured in 25 cm2 flasks with DMEM,
upplemented with 10% FBS, 2mM L-glutamine and 1% antibiotic-
ntimycotic solution, under an atmosphere of 5% CO2 at 37 ◦C.
ells were sub-cultured once a week using 0.25% trypsin-EDTA and
eeded at a density of 2×106 cells per mL.
.4. Protective effect of quercetin-biapigenin and
uercetin-biapigenin poly(-caprolactone)-loaded nanoparticles
ssays against tert-butylhydroperoxide-induced toxicity
HepG2 cells were plated in 96-multiwell culture plates at a con-
entration of 2×105 cells per mL.
To study the compounds and nanoparticle influence in cell
iability, 40h after plating, several concentrations of com-
ounds or nanoparticles were added (concentration equivalent to
–100g/mL of free compounds) and 24h later metabolic activity
f the cellswas estimatedby theMTTassay. Resultswere expressed
s percentage of cellmetabolic activity from the control (cellswith-
ut any compound).
To study the compounds ability to protect HepG2 cells against
-BOOH-induced toxicity two incubation regimens were used: pre-
ncubation and co-incubation regimen, as described previously
22], with minor modifications. Briefly, in the pre-incubation reg-
men, cells were incubated with the compounds in a free state or
ith the quercetin and biapigenin PCL-loadednanoparticles for 4h,
ollowed by a recovery period of 16h with fresh medium without
he compounds to allow cells antioxidant defenses to be synthe-
ized. Then cells were incubated with 1.5mM t-BOOH for 3.5h. In
he co-incubation regimen HepG2 cells were incubated with the
ompounds or nanoparticles and 1.5mM t-BOOH for 3.5h and 5h.
.5. Evaluation of quercetin-biapigenin mixture and
uercetin-biapigenin poly(-caprolactone)-loaded nanoparticles
gainst tert-butylhydroperoxide–induced lipid peroxidation
In order to study the potential protective effect of the
ompounds in its free form and in nanoparticles against t-BOOH-
nduced lipid peroxidation co-incubation regimen was used. Cells
ere plated in 6-multiwell plates at a concentration of 7.5×105
ells per mL. After 40h, cells were incubated with the compounds,
uercetin-biapigenin PCL-loaded nanoparticles and/or t-BOOH for
.5h. After that cell medium was harvested and kept at −80 ◦C for
urther processing.
The extent of lipid peroxidation was estimated by the lev-
ls of MDA measured, using tiobarbituric and reactive substances
TBARS) assay, as previously described [20] with some modi-
cations. Briefly, trichloroacetic acid 50% (w/V) was added to
he harvested medium and then the mixture was centrifuged at
0000 rpm for 1min. After, tiobarbituric acid 1% (w/V) was added
o the supernatant. This was left for 10min in a boiling water bath.
fter cooling, the solution was read at 535nm..6. Statistical analysis
In most of the experiments three independent sets, each com-
osed by three replicas, have been done. Statistical analysis wasFig. 1. Chromatographic profile of the compound mixture obtained; peak
1–quercetin; peak 2–biapigenin.
performed using Graph Pad Prism 5.0
®
software. In the nanoparti-
cles characterization, one-way ANOVA was employed with Tukey’s
post hocmultiple comparison test. In the in vitro antioxidant assays
unpaired Students t-test was used. In the in vitro cell assays One-
way ANOVA was employed with Dunnett’s multiple comparison
test, when comparing each concentration against a control and
unpaired t-test when comparing two similar concentrations. Dif-
ferences were considered to be significant at a level of p<0.05.
3. Results and discussion
3.1. Production of quercetin-biapigenin poly (-caprolactone)
(PCL) nanoparticles
Through the isolation procedure described in material and
methods a purified H. perforatum fraction, containing quercetin
and biapigenin (1:1w/w) as quantified by HPLC-DAD) (Fig. 1), was
obtained. This fraction, proved to have relevant antioxidant and
neuroprotective activities [6–9]. Quercetin-biapigenin loaded PCL
nanoparticles were prepared by nanoprecipitation, also known as
solvent displacement method. It is considered one of the easi-
est and mostly used method to obtain nanoparticles, especially
with PCL polymer [15,19]. Additionally, it is a reproducible, fast
and economic procedure that uses pre-formed polymers as start-
ing materials. The polymer solvent (acetone) was chosen among
organic solvents that are miscible in water and easy to remove
by evaporation. For this reason, acetone is the most frequently
used polymer solvent [23]. The nanoparticles form instantaneously
during the rapid diffusion of the compound mixture-polymer solu-
tion in water. The use of a surfactant is not critical to nanoparticle
formation [23]. Despite that, it helps to preserve nanoparticle sus-
pension from aggregation, being therefore relevant for the physical
stability of the preparation [24]. In this preparation the option
was to use a well described poloxamer composed of (propy-
lene oxide)/poly(ethylene oxide) block copolymer, Pluronic
®
F-68.
Nanoparticle preparationwas found to be reproducible for size and
zeta potential.
3.2. Characterization of nanoparticlesParticle size and size distribution are considered important
characteristics of nanoparticulate systems, since they determine
in vivo distribution, toxicity and its targeting ability. They can also
influence drug loading, drug release and nanoparticle stability [25].
Table 1
Mean particle size, polydispersity, zeta potential, association efficiency and loading capacity of quercetin-biapigenin poly(-caprolactone)-loaded nanoparticles.
PCL:
Compounds
Size (nm) Polydispersity
Index
Zeta
potential
(mV)
Association
Efficiency (Q)
(%)
Association
Efficiency (B)
(%)
Association
Efficiency
(Q+B) (%)
Loading
Capacity (%)
Nanoparticle
Yield (%)
1:0.1 185±4 0.11±0.03 −20.1±1.2 99.3±0.1 99.9±0.1 99.7±0.1 5.3±0.1 60.2±1.5
1:0.2 219±21† 0.27±0.10§ −19.3±1.2 54.3±14.6† 67.5±11.5† 67.3±14.4† 9.2±1.8 50.6±8.1
1:0.5 250±22 #, ‡ 0.37±0.04#, ‡ −18.0±0.1† 56.0±8.6† 73.2±4.4† 65.0±3.4† 33.5±13.0† , ¥ 52.0±6.7
Q- quercetin, B- biapigenin; n=3; results are showed as mean± standard deviation.
# Significantly different compared with 1:0.1 (p<0.001).
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(† Significantly different compared with 1:0.1 (p<0.01).
‡ Significantly different compared with 1:0.2 (p<0.01).
§ Significantly different compared with 1:0.1 (p<0.001).
¥ Significantly different compared with 1:0.2 (p<0.05).
s Table 1 shows, the mean particle size of quercetin-biapigenin
oaded PCL nanoparticles were about 200nm, which was expected,
aking into account the preparation method [24]. PI reveals a nar-
ow distribution [25] and values under 0.4. The mean particle size
nd PI increases with the increase of theoretical loading capacity.
his leads to more compound interaction and being the amount
f polymer constant in all proportions, there could be expected a
ecrease in the ability of PCL to fully encapsulate all compounds in
he colloidal suspension. In fact, thebest proportion, in termsof size
nd stability is the one with less compounds to be encapsulated,
:0.1 (mean particle size of 184.9±9.1nm and PI of 0.11±0.03).
Zeta potential values of the three proportions tested had a nega-
ive value, which may be attributed to the ionized carboxyl groups
f PCL segments on the nanoparticles surface [26]. As for an abso-
ute value, zeta potential was around −20mV, a good indicative of
he nanoparticle stability [15].
Association efficiency (AE) and loading capacity (LC) are known
o depend on the drug solubility in the polymer, which is related
ig. 2. Transmission electronic microscopy analysis of quercetin-biapigenin poly(-capro
B), 1:0.1 (C) and empty nanoparticles (D) at a total amplification of 100000X.to polymer composition, molecular weight, drug polymer interac-
tion and the presence of end functional groups (ester or carboxyl)
[27]. In the present study, the nanoparticle AE was observed to be
inverselyproportional to compoundsconcentration. ThehighestAE
was obtained in 1:0.1 PCL:compounds ratio. A higher LC was how-
ever expected in this proportion. Taking only in consideration AE
percentage, one could estimate a LC close to 9%. Taking into account
the yield (60.2±1.5%) it can be observed that LC is about 60% of the
one expected for an AE of almost 100%. These results are, thereby,
complementary. Taking into consideration all these results the best
stable formulation had a polymer:compounds ratio of 1:0.1.
3.3. Nanoparticle morphology by transmission electronic
microscopy (TEM)
TEMmorphological analysis of quercetin-biapigenin loaded PCL
nanoparticles and empty PCL nanoparticles revealed that all were
formed by spherical nanoparticles (Fig. 2A–D). Ratio 1:0.1 is the
lactone)-loaded nanoparticles, with a polymer:compounds ratio of 1:0.5 (A), 1:0.2
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tig. 3. FTIR spectra of quercetin-biapigenin (A), physical mixture of quercetin-
iapigenin and PCL polymer (B), unloaded PCL nanoparticles (C) and quercetin-
iapigenin loaded PCL nanoparticles (D) (I). FTIR spectra was truncated in the range
f 1800–600 cm-1, which represents the fingerprint region of the compounds (II).
ne that presents smaller nanoparticles, with the most uniform
ize distribution of the three. Quercetin-biapigenin PCL-loaded
anoparticles TEM results are coherent with studies described in
iterature for PCL-loaded nanoparticles [27]. The TEM data of our
tudy are consistent with the particle size measures.
.4. Fourier transform infrared spectroscopy (FTIR) spectroscopy
FTIR is a very useful technique to assess the encapsulation of
rugs and its intermolecular interactions in a nanoparticle system.
he functional groups present in quercetin and biapigenin are sim-
lar so it is expected to obtain similar absorption bands in the same
egions of those functional groups.
In Fig. 3 it is showed that quercetin-biapigenin presented an
bsorption band of O H stretch at 3409 cm−1 (Fig. 3-I) which is
haracteristic of various phenolic compounds, and a characteris-
ic absorption band of C O at 1653 cm−1 (Fig. 3-II). The band at
−1608 cm is assigned to C C stretching vibrations occurred in the
romatic rings, and the band at 1358 cm−1 is characteristic of O H
ending vibrations (Fig. 3-B). Furthermore, the strong absorption
and at 820 cm−1 is assigned to the aromatic rings. The FTIR spec-
ra of the physical mixture of quercetin-biapigenin and PCL and theFig. 4. Cumulative release profile of biapigenin from poly(-caprolactone)-loaded
nanoparticles in phosphate-buffered saline (PBS, pH 7.4) containing ethanol 10%
(V/V). Data is presented as mean± SD of three independent experiments.
unloaded PCL nanoparticles were very similar (Fig. 3-II). The pro-
portion of quercetin-biapigenin and PCL in the physical mixture
was the same as used to produce the loaded PCL nanoparticles, and
that may be the explanation why the spectra was so similar to the
unloaded PCL nanoparticles spectra because the signal of PCL is
much higher than that of quercetin-biapigenin. Nevertheless, it is
possible to conclude that no intermolecular interactions occurred
in the mixture since no significant bands occurred in the spectra.
The FTIR spectra of quercetin-biapigenin loaded PCL nanoparti-
cles shows up the intermolecular interaction between quercetin-
biapigenin and PCL polymer upon encapsulation. This was shown
by the appearance of 1186 and 733 cm−1 bands that occurred
in quercetin-biapigenin loaded PCL nanoparticles and did not
occurred in the physical mixture neither in the unloaded PCL
nanoparticles spectra. In addition, that interactions within the
nanoparticle system was mainly showed by a great increase of
the intensity of 1727 cm−1 absorption band. The latter is moti-
vated by an increase of a C O stretching within the system, and
the1186and733 cm−1 bandsmayoccurreddue toOC Ostretching
and an aromatic C H bending, respectively. Other small absorption
bands occurred at 1418 and 1396 cm−1, which is characteristic of
C H bending. Considering all the FTIR spectra and particularly the
spectra of quercetin-biapigenin loaded PCL nanoparticles it is pos-
sible to conclude that quercetin-biapigenin drug was successfully
entrapped into the PCL nanoparticles. That can also be concluded
taking into account the similarity between empty and quercetin-
biapigenin nanoparticles and its difference to the physical mixture.
3.5. In vitro release profile
Drug release and subsequent biodegradation are important
features for developing successful formulations. The release
rates of nanoparticles depend upon desorption of the surface-
bound/adsorbed drug, diffusion through the nanoparticle matrix,
nanoparticle matrix erosion or a combined erosion/diffusion pro-
cess [28].
As shown in Fig. 4, therewas as initial burst release of about 68%
in the first hour. The burst release of hydrophobic compounds, such
as quercetin and biapigenin, is attributed to the predominant sur-
face presence of the compounds in the nanoparticle formulation
[29]. After the first hour a sustained and slow release continued
reaching 75% after 8h. Until the end of the assay, at 24h time,
there was not a significant alteration of the amount of compounds
released. This can be explained by the predominant diffusion
releasemechanismrather thanpolymerdegradationverified, espe-
ciallywith lowmolecularweight compounds, suchas those in study
[27].
As for the release medium in which the assay was performed,
there had to be taken in consideration solubility aspects. The com-
Table 2
Antioxidant activity (EC50) of free purified fraction and quercetin-biapigenin poly(-caprolactone)-loaded nanoparticles.
EC50 (g/mL)
DPPH radical
scavenging activity
Superoxide radical
scavenging activity
Iron (II) chelating
activity
Quercetin-biapigenin 5.95±0.97 72.71±4.07 11.56±0.44
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(Quercetin-biapigenin PCL-loaded nanoparticles 5.73±1.20
.d. – not detected the concentration range tested (5–250g/mL)
# Significantly different compared with quercetin-biapigenin (p<0.001).
ounds in study are sparingly soluble in PBS, so ethanol was added
o the buffer (10%, V/V). Ethanol increased compounds solubility
nto the release medium [30], without affecting the release profile,
ince PCL is not soluble in it [31]. Release medium properties were
aintained as physiologic as possible.
Fig. 4 only reports to the release profile of biapigenin, since
uercetin, present in the initial mixture, was degraded due to PBS
onditions. Quercetin instability in physiologic medium (half-life
n PBS pH 7.2 of 10h [32]) can be due to medium alkalinization,
eading to oxidation by atmospheric oxygen [33] or by an auto-
xidative phenomenon that can occur in aerobic aqueous medium
34]. Despite that and due to the chemical similarity between
uercetin and biapigenin (as perceived by the chemical structures
n Fig. 1), one could expect a similar release profile for both com-
ounds.
.6. In vitro antioxidant activity
.6.1. 2,2-diphenyl-1-picrylhydrazyl (DPPH)-radical scavenging
ctivity assay
DPPH method is a decolorization assay which measures the
elative antiradicalar abilities of natural compounds and extracts
o scavenge free radicals. It is a commonly used method to mea-
ure antioxidant activity due to excellent reproducibility, stability,
ommercial availability and by the fact that it is an easy screen-
ng/measurement method [7]. The antiradicalar activities of the
ree and nanoencapsulated compounds are shown in Table 2.
uercetin is known to be a good DPPH radical scavenger, with
ow EC50 values reported, whereas biapigenin is not a good DPPH
cavenger [47]. In our study EC50 of compound mixture, quercetin
nd biapigenin, was of 5.95±0.97g/mL, which can be essen-
ially attributed to quercetin’s activity (Table 2). This antiradicalar
ctivity was lower, in comparison to positive control, quercetin
1.85±0.18g/mL), which can be explained by the presence of
iapigenin in the mixture. Compounds in its free form and in
CL-loaded nanoparticles had similar antiradicalar activities. This
esultwas consistentwithother reports for quercetinnanoparticles
29,35].
.6.2. Evaluation of superoxide radical scavenging activity
Superoxide radical is formed in almost all aerobic cells as a result
f the donation of one electron of oxygen and is a major agent in
he mechanism of oxygen toxicity. Itself is a week radical but may
ause severe damage to the cell by generating hydroxyl radical and
inglet oxygen [36].
The scavenging activity of free purified fraction and loaded PCL
anoparticleswas establishedby theNBT reductionmethod,where
he non-enzymatic PMS/NADH system generates superoxide radi-
als, which reduce the yellow NBT2+ in order to produce the purple
BT formazan. Antioxidants are able to inhibit the purple NBT for-
ation by competition with NBT for superoxide radical [36].
The quercetin-biapigenin mixture showed a good super-
xide radical scavenging activity (EC50=77.64±9.46g/mL)
Table 2), similar to the positive control, ascorbic acid
EC50=77.50±10.88g/mL). Superoxide scavenging activityn.d. 23.50±0.55 #
is related to the same structural molecular features as of DPPH
scavenging activity [37], and likewise, in our study, attributed
to quercetin. In quercetin-biapigenin loaded PCL nanoparticles,
despite of an increase of activity verified with the increase of
concentration tested, there was not possible to determine an EC50
value, in concentration range tested. The time in which the assay
takes place (threemin, as described in the material and methods
section) and according to the release profile of these nanoparticles,
will not be enough to allow the release of quercetin-biapigenin
from the polymeric matrix. These results are coherent with the
compound encapsulation in PCL matrix.
3.6.3. Iron (II) chelating activity
Iron can stimulate lipid peroxidation by the Fenton reaction and
bydecomposing lipid hydroperoxides into peroxyl and alkoxyl rad-
icals that can perpetuate chain of reaction.Metal chelating capacity
is therefore significant since it reduces the concentration of the
transition metal that catalyzes lipid peroxidation. Ferrozine pro-
duces a violet complex with Fe2+. In the presence of a chelating
agent, complex formation is interrupted and as a result the violet
color of the complex is decreased [38].
Regarding iron chelation (IC), the compounds mixture pre-
sented a good activity (Table 2), despite lower than EDTA
(EC50=1.18±0.01g/mL). Iron (II) chelating activity of the mix-
ture can be attributed to quercetin, which is known to be powerful
chelating agent that can sequester Fe2+ in such a way to prevent
its involvement in the Fenton reaction [38]. It can possibly also
be due to biapigenin if we take in consideration previous reports
that attributed IC a possible role in the inhibition of lipid peroxida-
tion of compounds such as apigenin, amentoflavone and biapigenin
[6,39]. In quercetin-biapigenin loaded PCL nanoparticles the IC
value was significantly higher (p<0.001). This, can be explained
by the methodology employed. There is a 10min incubation period
previously to the IC measurement. This will allow the release of
some amount of quercetin and biapigenin from the nanoparticle,
but not enough for a complete release of the compounds, resulting
in a lower IC activity. These results are coherentwith the compound
encapsulation in PCL matrix.
3.7. Long-term toxicity of compounds and nanoparticles
Since liver is the organ primary responsible for compound
metabolization and due to its susceptibility to toxic effects, its rele-
vant to determine the toxicity/protective activity of quercetin and
biapigenin, in its free form and in PCL-loaded nanoparticles.
In order to select appropriate concentrations for the cytopro-
tective assays, non-toxic concentrations were first determined,
ensuring that no direct cell damage was caused by compounds
tested.
The compounds tested, encapsulated or not, showed increasing
cytotoxicity in a concentration dependent manner (Fig. 5). In con-
centrations higher than 25g/mL, for non-encapsulated quercetin
and biapigenin (p<0.05), and 50g/mL, for quercetin-biapigenin
PCL-loaded nanoparticles (p<0.01), there was significant toxicity
on HepG2 cells.
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cig. 5. Cytotoxicity of different concentrations of quercetin-biapigenin in its free f
y MTT assay after 24h. Data is presented as mean± SD of three independent exper
<0.05, ## p<0.01 and ### p<0.001 when comparing two similar concentrations
In the smaller concentrations tested free compounds are more
ffective, in terms of cell proliferation, than nanoparticles (signifi-
ant for 5 and 10g/mL, # p<0.05).
Empty PCL nanoparticles revealed no significant interference in
ell proliferation in the concentrations range tested (neither toxic
or protective activity) (data not shown).
Results show that nanoencapsulation of quercetin and biapi-
enin significantly reduced intrinsic toxicity of the compounds at
igh concentrations (25, 50 and 100g/mL). In contrast, with free
ompounds, cell viability is decreased in 30% at the concentration
f 25g/mL and about 80% at 100g/mL. These results, regarding
uercetin toxicity, are coherent with others studies, in HepG2 and
ther cell lines [39,40–42], suggesting an intrinsic, non-selective,
ompound toxicity. There are no reports, to our knowledge, of
iapigenin toxicity. However, this possibility cannot be excluded,
s biapigenin is a flavonoid, and its known that this group of com-
ounds can act also as prooxidants, on a concentration dependent
anner [43].
One of the aims of preparing nanoparticles is to minimize toxi-
ity of the compounds they convey. This was successfully achieved
or higher compounds concentrations (100–50g/mL; Fig. 5). Con-
rarily, in concentrations lower than 10g/mL, free compounds
eem to promote higher cell viability in comparison with its
anoparticulate equivalent. This can be explainedby an incomplete
eleaseof quercetin-biapigenin fromthenanoparticulate system, at
h time.
Particle cellular uptake can be affected by several factors, such
s size and shape, cell line in study, nanoparticle composition
nd surface properties [44]. In this study, particle size and surface
roperties, namely charge, are considered to be determinants for
ellular uptake efficiency. Taking in consideration that both cell
embrane and quercetin-biapigenin PCL-loaded nanoparticles are
egatively charged the repulsive forces between them could deter-
ine a lower cellular uptake from the PCL-loaded nanoparticles, in
omparison with the compounds in its free form. Internalization of
CL-loaded nanoparticles, as described in other studies, is believed
o occur through nonspecific binding and clustering of the particles
n scattered cationic sites present on the plasma membrane, and
onsequent endocytosis [44].nd in PCL-loaded nanoparticles on HepG2 cells. Cell proliferation was determined
ts. *p<0.05, **p<0.01 and ***p<0.001 when compared with the negative control. #
3.8. Protective effect of quercetin-biapigenin and
quercetin-biapigenin poly(-caprolactone)-loaded nanoparticles
against tert-butylhydroperoxide-induced toxicity
t-BOOH is a short chain analog of lipid hydroperoxides which
mimics the toxic effect of peroxidized fatty acids. This prooxi-
dant is considered a useful model for investigating the mechanism
of oxidative cell injury. It can act by two distinct mechanisms.
The first comprises the generation of peroxy radicals in cytosol
through its interaction with ferrous iron in a reaction similar to
the Fenton reaction or cytochrome P450, thus playing an impor-
tant role in free radical formation, inducing oxidative DNA damage
and lipid peroxidation. The second is dependent on the depletion
of the reduced from of glutathione. t-BOOH can be metabolized
by Se-glutathione peroxidase (GPx) with formation of glutathione
disulfide (GSSG) from its reduced form reduced glutathione (GSH).
These phenomena are similar to those related to cell and tis-
sue oxidative stress. Depletion of GSH and nicotinamine adenine
dinucleotide phosphate (reduced form) (NADPH) oxidation are
associated with altered calcium homeostasis, and related with
changes in mitochondrial permeability, accompanied by a depo-
larization of mitochondrial potential, which can lead to cell injury
and death [45,46].
Oxidant t-BOOH is considered a model compound that can be
used to induce oxidative stress in cell systems by producing free
radical intermediates, increase of which might be a primary factor
for hepatotoxicity [48]. HepG2 cell line has been used in several
studies to evaluate the toxicity or protective effects of several com-
pounds against oxidative stress t-BOOH-induced [16,2048].
In the present study HepG2 cells were exposed to an oxida-
tive insult induced by t-BOOH. Co-incubation of HepG2 cells with
t-BOOH and quercetin-biapigenin or its polymeric nanoparticles
reflects a direct antioxidant effect of the compounds on t-BOOH-
induced cell toxicity. Two incubation times (3.5 and 5h) were
selected in order to understand the compounds and nanoparticle
activity on HepG2 cells.Free compounds revealed better protective activity than the
correspondent nanoparticles in all the concentrations tested
(Figs. 6 and 7). In the second co-incubation time selected, 5h, there
is an even smaller activity by quercetin-biapigenin PCL-loaded
Fig. 6. Cytoprotection of different concentrations of quercetin and biapigenin in its free form, and in PCL-loaded nanoparticles on HepG2 cells (3.5h co-incubation regimen).
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anoparticles, comparing with the first period of time, coherently
ith the justification for this incubation regimen. With an increasen time, from 3.5 to 5h, t-BOOH would supposedly enter even more
n the cells becoming very difficult for the cells to protect them-
elves from that insult.
ig. 7. Cytoprotection of different concentrations of quercetin and biapigenin in its free f
ells were treated with or without compounds along with 1.5mM t-BOOH for 5h and ce
ositive control. Data is presented as mean± SD of three independent experiments. *p<0
nd ## p<0.01 when comparing two similar concentrations.ell proliferation was determined by MTT assay. Quercetin 10M (Q) was used as a
.05, **p<0.01 and ***p<0.001 when compared with the t-BOOH control. # p<0.05
When exposing HepG2 cells simultaneously to quercetin-
biapigenin or its PCL-loaded nanoparticles and t-BOOH for 3.5h
and with compound concentration between 1 and 25g/mL, t-
BOOH-induced toxicitywas inhibited almost completely,with cells
metabolic activityvaluesnear to thoseof t-BOOH-untreatedcells. In
these concentrations free quercetin-biapigenin were significantly
orm, and in PCL-loaded nanoparticles on HepG2 cells (5h co-incubation regimen).
ll proliferation was determined by MTT assay. Quercetin 10M (Q) was used as a
.05, **p<0.01 and ***p<0.001 when compared with the t-BOOH control. # p<0.05
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ells were pre-incubated with or without compounds for 4h and then exposed to
0M (Curc) was used as a positive control. Data is presented as mean± SD of three
-BOOH control. # p<0.05, ## p<0.01 and ### p<0.001 when comparing two sim
ore protective than the corresponding polymeric nanoparticles
p<0.01 at 1g/mL and p<0.05 between 5 and 25g/mL) (Fig. 6).
In the co-incubation regimen of 5h exposure time, a decrease
n cell viability was perceived in the group of cells exposed to
-BOOHandquercetin-biapigenin PCL-loadednanoparticles, to val-
es close to those of the toxic alone (Fig. 7). This is evidence of a
on-protective activity of the nanoparticles. As for the compounds
n its free form, as stated above, they had a significant protective
ctivity against t-BOOH, in all concentrations tested, in compar-
son to the nanoparticles. This could be explained by the higher
ompound/particle competition for proper cell uptake, leading to
n advantage for the compounds with better internalization prop-
rties.
In the pre incubation regimen, HepG2 cells were first exposed
o the compounds and its polymeric nanoparticles, followed by a
ecovery period with fresh medium before addition of oxidant t-
OOH.
Pre-treating HepG2 cells with quercetin-biapigenin PCL-loaded
anoparticles revealed protective activity in all of the concentra-
ions tested, in comparison with the compounds in its free form.
hen comparingwith t-BOOHcontrol group, quercetin-biapigenin
CL-loaded nanoparticles presented protective properties in con-
entrations bellow 10g/mL (Fig. 8). Here, cells toxicity was
ignificantly decreased (in comparison with t-BOOH-untreated
ells). The isolated compounds did not possess a significant protec-
ive effect on the cells (except in the lowest concentration tested),
nd an increase in cell proliferation in a dose-dependent manner
as observed.
A smaller concentration (0.5g/mL) was added, on the pre- and
o-incubation regimen assays, to better understand the activity of
ow compound concentrations. These assays were not performedform, and in PCL-loaded nanoparticles on HepG2 cells (pre-incubation regimen).
t-BOOH for 3.5h and cell proliferation was determined by MTT assay. Curcumin
pendent experiments. *p<0.05, **p<0.01 and ***p<0.001 when compared with the
ncentrations.
with the higher concentration studied (100g/mL) due to signifi-
cant toxicity of the compounds.
In the pre-incubation regimen, better results, in terms of cyto-
protection, were obtained. This can be possibly justified by the
intrinsic antioxidant properties of the compounds, which lead to
an increase in cells protective mechanisms and their prooxidant
activity as well as a possible higher internalization [23]. Deleteri-
ous activity of quercetin and biapigenin, such as other flavonoids,
can be associated with toxicity, as previously described, but also as
a potential protector. In this case, compounds would impose a mild
oxidative stress to the cells, inducing antioxidant defenses and bio-
transformation enzymes, leading consequently to cytoprotection
[43]. Results regarding quercetin and biapigenin in its free form
could be justified by amore rapidmetabolization (taking in consid-
eration that these compounds, like other flavonoids, are considered
xenobiotics, thus being rapidly metabolized) than the PCL-loaded
nanoparticles, which would diminish the amount of compounds
able to interact and protect the cells. The PCL-loaded nanoparti-
cles, less toxic than the compounds in its free form, induce a higher
protection. Here, theminor stress caused by the encapsulated com-
pounds, once inside the cells, would lead to an increase of internal
cell defenses, which would better protect against t-BOOH insult.
These results, which are indicative that a small amount of com-
pounds is enough to convey protective effects in HepG2 cells, are
consistent with others [41].
3.9. Lipid peroxidationLipid peroxidation of polyunsaturated lipids in membranes is
considered an important type of molecular lesion induced by free
radicals [16]. During this process unsaturated lipids can be oxidized
and cut into fragments, like alkanes, malondialdehyde (MDA) and
F ne)-lo
H as me
n tert-b
a
a
a
i
[
a
c
o
s
i
i
a
e
i
A
i
1
c
p
B
c
w
t
T
o
1
T
t
a
i
s
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epG2 cells. Quercetin (Q) 10M was used as positive control. Data is presented
egative control. # p<0.05 ## p<0.01 and ### p<0.001 when compared with the
lkenals, chemically very reactive and, if not removed from the cell,
ble to cause cellular damage [16]. MDA has been widely used as
n index of lipid peroxidation since it has been found to be elevated
n several diseases thought to be related with free radical damage
2,3].
Lipid peroxidation requiresmetal ions, like Fe(III) and Fe(II), that
ct as catalysts in redox reactions between oxygen and biologi-
almacromolecules. These ions facilitate, therefore, the conversion
f superoxide anion and hydrogen peroxide to hydroxyl radical, a
pecies proposed to initiate lipid peroxidation [49].
In order to study the effects of quercetin and biapigenin in
ts free form and its PCL-loaded nanoparticles against t-BOOH-
nduced lipid peroxidation, in a co-incubation regimen (with 3.5
nd 5h time) two concentrations were used: i – 10g/mL that
ffectively protected against cell death in the range of 80–90% and,
i – 0.5g/mL, which did not reveal significant protective activity.
s shown in Fig. 9, t-BOOH-induced lipid peroxidation was signif-
cantly decreased, (approximately 60%) with quercetin-biapigenin
0g/mL. Only PCL-loaded nanoparticles with a compound con-
entration of 0.5g/mL significantly inhibit t-BOOH-induced lipid
eroxidation in HepG2 cells (p<0.05, when compared with t-
OOH-treated cells). These results are coherent with those of the
o-incubation MTT assay.
In this study t-BOOH-induced lipid peroxidation in HepG2 cells
as attenuated in all the tested scenarios, exception made with
he co-incubation of t-BOOH and quercetin-biapigenin 0.5g/mL.
he inhibition was more intense when using quercetin-biapigenin
r its PCL-loaded nanoparticles with compounds concentration of
0g/mL, coherently with those of the co-incubation MTT assay.
here seems to exist, therefore, a correlation between the cytopro-
ection and the prevention of lipid peroxidation in HepG2 cells. The
bility that quercetin and possibly biapigenin have to chelatemetal
ons, specifically iron (II) can explain the results obtained in this
tudy. Moreover biapigenin presented a better iron-mediated lipid
eroxidation inhibition potential than quercetin [21]. The molecu-aded nanoparticles against tert-butylhydroperoxide-induced lipid peroxidation in
an± SD of three independent experiments.***p<0.001 when compared with the
utyl hydroperoxide control.
lar conformation of biapigenin, considering that it can insert itself
in the cellular membrane [6] can also help to explain these results.
4. Conclusions
A purified fraction containing a mixture of quercetin and
biapigenin, two antioxidant and neuroprotective compounds, was
isolated from H. perforatum. The mixture was successfully encap-
sulated into PCL nanoparticles using solvent displacementmethod,
resulting in nanoparticles ranging from 185 to 250nm in size. The
better proportion of PCL:compounds of those studied was of 1:0.1,
with an AE of 99.7% and a loading capacity of 5.3%. As for the release
profile, a biphasic release was verified, including an initial burst
effect followed by a slow, constant release. As to our knowledge,
this is the first report of the encapsulation of a quercetin and biapi-
genin mixture in a polymeric matrix, specifically, in PCL.
Antioxidant activity assays revealed that the functional prop-
erties of the compounds were maintained after encapsulation.
High encapsulation efficiency, small size, a sustained release and
the reproducibility of the production method make quercetin-
biapigenin loadedPCLnanoparticles a suitable candidate for further
studies. The hepatoprotective activity of quercetin-biapigenin
and its PCL-loaded nanoparticles was also studied. PCL-loaded
nanoparticles protect HepG2 cells from intrinsic quercetin and
biapigenin toxicity at high concentrations. In lower concentra-
tions compounds in its free form were more effective. Depending
on the incubation regimen, regarding t-BOOH-induced toxicity,
quercetin-biapigeninPCL-loadednanoparticles (pre-incubation) or
compounds in its free form (co-incubation) were more effective in
protecting HepG2 cells. Differences can be explained by cell uptake
and competitive factors, respectively.
Taking also in consideration quercetin and biapigenin antiox-
idant and neuroprotective properties, it will be relevant to
investigate thepotential of thenanoparticlesdescribed in this study
to reach the brain-blood barrier and the brain. This nanoparticu-
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iseases, such as Alzheimer and Parkinson disease.
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